Concord Drugs Share Price
78.80-1.51 (-1.88%)
+23.12% past 1 Year
Concord Drugs Limited was created in 1995 to manufacture and market innovative pharmaceutical products. Concord 's three core product areas are generics branded and specialty pharmaceuticals. The Company ranks among
Corporate filings & documents
Announcements
Copy of News-paper publications for quarterly results ended 30th June 2026.
3 weeks agoCopy of News-paper publications for quarterly results ended 30th June 2026.
3 weeks agoBoard of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
3 weeks agoBoard of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
3 weeks agoOutcome of Board meeting
3 weeks agoOutcome of Board meeting
3 weeks agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 inter alia to consider and approve Quarterly Results
1 month agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 inter alia to consider and approve Quarterly Results
1 month agoCertificate under Reg 74(5) of SEBI (DP) Regulations
1 month agoCertificate under Reg 74(5) of SEBI (DP) Regulations
1 month agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoCopy of Newspaper publication for audited results for year ended 31st March 2026.
3 months agoCopy of Newspaper publication for audited results for year ended 31st March 2026.
3 months agoAnnual Secretarial Compliance report under Regulation 24(A)
3 months agoFinancial Results for Year ending 31st March 2026
3 months agoCompany has approved financial results for Quarter and year ending 31st March 2026
3 months agoCompany in its Board Meeting has approved financial results for period ended 31st March 2026
3 months agoCompany in its Board Meeting has approved financial results for period ended 31st March 2026
3 months agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Financial Results for year ending 31.03.2026
3 months agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Financial Results for year ending 31.03.2026
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 06/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 06/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Reg 74(5)
4 months agoCertificate under Reg 74(5)
4 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Concord Drugs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230TG1995PLC020093</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Namratha Nagla</td></tr><tr><td>Designation :-</td><td>Compliance officer and Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>koni Reddy seelam</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 10/04/2026<br/><br/></div>
4 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Concord Drugs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230TG1995PLC020093</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Namratha Nagla</td></tr><tr><td>Designation :-</td><td>Compliance officer and Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>koni Reddy seelam</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 10/04/2026<br/><br/></div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>10.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 10/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoClosure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March 2026.
5 months agoClosure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March 2026.
5 months agoNews Paper publication of Q3 results
6 months agoNews Paper publication of Q3 results
6 months agoGeneral Update
6 months agoGeneral Update
6 months agoUn-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec 2025.
6 months agoUn-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec 2025.
6 months agoBoard of Directors approved financial results for 31 st December 2025
6 months agoBoard of Directors approved financial results for 31 st December 2025
6 months agoReconstitution of Committees
6 months agoAnnouncement under Regulation 30 of LODR
6 months agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Un-Audited financials Results for Quarter ending Dec 31 2025.
7 months agoCertificate under Reg 74(5) of SEBI (DP) regulations
7 months agoCompany has received purchase orders from various entities for supply of its products.
8 months agoClosure of Trading Window
8 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for S Koni Reddy
9 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for S Nagi Reddy
9 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for S Manoj Kumar Reddy
9 months agoDisclosure under SEBI (PIT) Regulations
9 months agoNew Paper publication of financial results for Quarter and Half year ended 30 Sep 2025.
9 months agoThe Board of Directors have approved allotment of Equity shares and Convertible warrants
9 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Survey No.249 Brahmanapally Village Hayatnagar Mandal Rangareddy Dist Telangana PIN: 501511 Tel No: 09052779505 Fax No: NULL Email: [email protected] Internet: www.concorddrugs.in
Registrars
1-2-285 , Domalaguda,,Hyderabad 1-2-285 Domalaguda NULL PIN: Tel No: 040-7642217/7634445 Fax No: 040-7632184 Email: NULL
Management
S Nagi Reddy, Chairman & Managing Director
S Nagi Reddy, Chairman & Managing Director
S Koni Reddy, Whole Time Director & Chief Financial Officer
S Manoj Kumar Reddy, Whole Time Director
S Nagavenkata Hareesh, Non Executive Independent Director
Sumeela Kasu, Non Executive Independent Director
Namratha Nagla, Company Secretary & Compliance Officer
Details
BSE 538965
NSE NULL
ISIN INE858L01010